Clinical Trial Update: An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating repeated oral doses of JNJ-64281802 against Dengue virus serotype 3 has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue Fever

Drugs mentioned

• JNJ-64281802

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Dengue | Phase 2 | Status: COMPLETED | Results posted: 2025-04-24